Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of ...

Learn how early detection of prostate cancer through screening and symptoms awareness leads to better outcomes.

David James, director of patient projects and influencing at Prostate Cancer Research, has set the record straight on some of ...

Prostate cancer is often seen as an unavoidable part of ageing, especially among men, but there are many myths that can create confusion.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

Debate over labeling certain cancers as 'benign' or 'premalignant' instead of 'cancer' due to stigma and fear. Experts weigh in on potential impact ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

Prostate cancer usually develops slowly, so there may be no signs of the health condition for many years, but once the tumour ...

PROSTATE cancer is the most common type of tumour in England following a surge in diagnoses after the Covid pandemic.